# PI15

## Overview
Peptidase Inhibitor 15 (PI15) is a gene that encodes a serine protease inhibitor protein, which plays a significant role in various physiological and pathological processes. The protein, also referred to as p25TI, sugarcrisp, and CRISP8, is characterized by its distinct structural domains, including a signal peptide, a CAP domain, a hinge domain, and a C-terminal extension. Despite its alternative names, PI15 does not belong to the CRISP subfamily (Gaikwad2020The). The protein's CAP domain is particularly notable for its α-β-α sandwich structure, which can bind divalent cations and potentially mimic protease active sites (Gaikwad2020The). PI15 is involved in modulating the activity of the Chlamydial protease CPAF during infection, highlighting its role in host-pathogen interactions (Prusty2018Peptidase). Additionally, PI15 has been identified as a potential diagnostic marker for cholangiocarcinoma, underscoring its clinical significance in cancer diagnostics (Jiang2019Peptidase).

## Structure
PI15, also known as p25TI, sugarcrisp, and CRISP8, is a protein that is structurally characterized by several distinct domains. It contains a signal peptide, a CAP domain, a hinge domain, and a 12 amino acid C-terminal extension (Gaikwad2020The). The CAP domain is notable for its α-β-α sandwich structure, which includes a central cavity capable of binding divalent cations, potentially mimicking protease active sites (Gaikwad2020The). The hinge domain, which connects the CAP and C-terminal domains, is stabilized by disulfide bonds (Gaikwad2020The).

In humans, PI15 is predicted to produce a mature protein of 198 amino acids following cleavage at a furin-like protease cleavage site (Gaikwad2020The). The protein may undergo post-translational modifications, such as glycosylation, as suggested by the presence of a potential N-glycosylation site (Yamakawa1998cDNA). PI15 does not belong to the CRISP subfamily, despite its alternative names (Gaikwad2020The). The protein's structure and modifications contribute to its function as a serine protease inhibitor, playing roles in various physiological and pathological processes.

## Clinical Significance
Peptidase Inhibitor 15 (PI15) has been identified as a potential diagnostic marker for cholangiocarcinoma (CCA), a type of liver cancer. Studies have shown that PI15 is significantly overexpressed in CCA tumor tissues compared to normal tissues, with a 3.8-fold increase in expression levels. This overexpression is not observed in normal liver tissues, suggesting a specific association with CCA. PI15's diagnostic value is highlighted by its superior sensitivity and specificity compared to other tumor markers such as AFP, CEA, and CA125. The positive rate of PI15 expression in CCA is notably high, reaching 83.3% in some studies, and its diagnostic performance is further enhanced when combined with CA19-9, another marker for CCA (Jiang2019Peptidase).

In the context of infectious diseases, PI15 plays a role in regulating the activity of the chlamydial protease CPAF during Chlamydia infection. PI15 modulates CPAF maturation and activity, affecting chlamydial growth. Alterations in PI15 expression can lead to changes in CPAF activity, which is crucial for the development of Chlamydia. This interaction suggests that PI15 is involved in the host-pathogen dynamics during infection, although the exact mechanisms remain to be fully understood (Prusty2018Peptidase).

## Interactions
Peptidase Inhibitor 15 (PI15) is known to interact with the Chlamydial protease CPAF (Chlamydia protease-like activity factor) during Chlamydia trachomatis infection. PI15 forms a functional complex with CPAF within the chlamydial inclusion lumen. It binds to the inactive CPAF zymogen during early stages of infection, facilitating its activation. This interaction is crucial for CPAF maturation, as PI15 promotes the auto-processing of CPAF zymogens, potentially through oligomerization that positions them for activation (Prusty2018Peptidase).

PI15 can both enhance and inhibit CPAF activity depending on its concentration. At low concentrations, PI15 induces CPAF activity, while at high concentrations, it inhibits CPAF by blocking its protease domain. This dual role suggests that PI15 regulates CPAF activity through a concentration-dependent mechanism (Prusty2018Peptidase).

PI15 also interacts with CPAF by forming high-molecular complexes, which are instrumental for CPAF activation. These complexes disappear during chlamydial growth upon CPAF activation, indicating a dynamic interaction between PI15 and CPAF (Prusty2018Peptidase). Additionally, PI15 has been shown to co-localize with CPAF aggregates within the inclusion lumen, further supporting its role in modulating CPAF activity (Prusty2018Peptidase).


## References


[1. (Jiang2019Peptidase) Yong Jiang, Xiaohu Zheng, Defeng Jiao, Peng Chen, Yechuan Xu, Haiming Wei, and Yeben Qian. Peptidase inhibitor 15 as a novel blood diagnostic marker for cholangiocarcinoma. EBioMedicine, 40:422–431, February 2019. URL: http://dx.doi.org/10.1016/j.ebiom.2018.12.063, doi:10.1016/j.ebiom.2018.12.063. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ebiom.2018.12.063)

[2. (Gaikwad2020The) Avinash S Gaikwad, Jinghua Hu, David G Chapple, and Moira K O’Bryan. The functions of cap superfamily proteins in mammalian fertility and disease. Human Reproduction Update, 26(5):689–723, May 2020. URL: http://dx.doi.org/10.1093/humupd/dmaa016, doi:10.1093/humupd/dmaa016. This article has 21 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/humupd/dmaa016)

[3. (Prusty2018Peptidase) Bhupesh K. Prusty, Suvagata R. Chowdhury, Nitish Gulve, and Thomas Rudel. Peptidase inhibitor 15 (pi15) regulates chlamydial cpaf activity. Frontiers in Cellular and Infection Microbiology, May 2018. URL: http://dx.doi.org/10.3389/fcimb.2018.00183, doi:10.3389/fcimb.2018.00183. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcimb.2018.00183)

[4. (Yamakawa1998cDNA) Toru Yamakawa, Satoshi Miyata, Naoki Ogawa, Naohiko Koshikawa, Hidetaro Yasumitsu, Toshinori Kanamori, and Kaoru Miyazaki. Cdna cloning of a novel trypsin inhibitor with similarity to pathogenesis-related proteins, and its frequent expression in human brain cancer cells. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1395(2):202–208, January 1998. URL: http://dx.doi.org/10.1016/s0167-4781(97)00149-8, doi:10.1016/s0167-4781(97)00149-8. This article has 30 citations.](https://doi.org/10.1016/s0167-4781(97)00149-8)